Director

Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Institution	Shares	Value	Change
Assenagon Asset Management	4,989,006	$79M	INCREASED
Argent Capital Management	2,550,355	$40M	INCREASED
Robeco Institutional Asset Management B.V	2,080,468	$33M	INCREASED
Wedge Capital Management L L P/NC	1,856,208	$29M	DECREASED
Arnhold	1,460,974	$23M	DECREASED

Insider	Type	Shares	Value	Date
Leo Frans Groothuis (Director)	AWARD	2,756	$44K	2026-06-30
David S Simmons (Director)	AWARD	2,362	$38K	2026-06-30
Campbell Paul (Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller)	SELL	50,076	$810K	2026-06-25

Viatris Inc. Common Stock (VTRS) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades